1. Home
  2. CNTN vs CRBP Comparison

CNTN vs CRBP Comparison

Compare CNTN & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CNTN

Canton Strategic Holdings Inc. Common Stock

N/A

Current Price

$3.58

Market Cap

185.3M

Sector

Health Care

ML Signal

N/A

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$11.77

Market Cap

184.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNTN
CRBP
Founded
2017
2009
Country
United States
United States
Employees
12
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
185.3M
184.4M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
CNTN
CRBP
Price
$3.58
$11.77
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$45.50
AVG Volume (30 Days)
441.5K
301.6K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,822,272.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$116.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
97.62
52 Week Low
$2.89
$6.73
52 Week High
$5.27
$20.56

Technical Indicators

Market Signals
Indicator
CNTN
CRBP
Relative Strength Index (RSI) 55.74 59.55
Support Level $3.01 $9.32
Resistance Level $3.82 $12.41
Average True Range (ATR) 0.24 0.94
MACD 0.04 -0.02
Stochastic Oscillator 69.47 70.04

Price Performance

Historical Comparison
CNTN
CRBP

About CNTN Canton Strategic Holdings Inc. Common Stock

Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: